Scleroderma future or investigational therapies: Difference between revisions
Created page with "__NOTOC__ {{Scleroderma}} {{CMG}} ==Overview== ==Future or Investigational Therapies== Given the difficulty in treating scleroderma, treatments with a smaller [[evidence ba..." |
No edit summary |
||
| Line 7: | Line 7: | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
Given the difficulty in treating scleroderma, treatments with a smaller [[evidence based medicine|evidence base]] are often tried to control the disease. These include antithymocyte globulin and [[mycophenolate mofetil]]; some reports have reported improvements in the skin symptoms as well as delaying the progress of systemic disease, but neither of them have been subjected to large clinical trials.<ref name=Zandberg/> | Given the difficulty in treating scleroderma, treatments with a smaller [[evidence based medicine|evidence base]] are often tried to control the disease. These include antithymocyte globulin and [[mycophenolate mofetil]]; some reports have reported improvements in the skin symptoms as well as delaying the progress of systemic disease, but neither of them have been subjected to large clinical trials.<ref name=Zandberg>{{cite journal |author=Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y |title=New therapeutic strategies for systemic sclerosis--a critical analysis of the literature |journal=Clin. Dev. Immunol. |volume=12 |issue=3 |pages=165–73 |year=2005 |pmid=16295521 |doi=}} {{PMC|2275417}}</ref> | ||
While still experimental (given its high rate of complications), [[hematopoietic stem cell transplantation]] is being studied in patients with severe systemic sclerosis; improvement in life expectancy and severity of skin changes has been noted.<ref>{{cite journal |author=Nash RA, McSweeney PA, Crofford LJ, ''et al'' |title=High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the U.S. multicenter pilot study |journal=Blood |volume=110 |issue=4 |pages= 1388–96|year=2007 |pmid=17452515 |doi=10.1182/blood-2007-02-072389}}</ref> | While still experimental (given its high rate of complications), [[hematopoietic stem cell transplantation]] is being studied in patients with severe systemic sclerosis; improvement in life expectancy and severity of skin changes has been noted.<ref>{{cite journal |author=Nash RA, McSweeney PA, Crofford LJ, ''et al'' |title=High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the U.S. multicenter pilot study |journal=Blood |volume=110 |issue=4 |pages= 1388–96|year=2007 |pmid=17452515 |doi=10.1182/blood-2007-02-072389}}</ref> | ||
| Line 13: | Line 13: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Autoimmune diseases]] | |||
[[Category:Diseases involving the fasciae]] | |||
[[Category:Rheumatology]] | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
Revision as of 21:43, 7 November 2012
|
Scleroderma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Scleroderma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Scleroderma future or investigational therapies |
|
Risk calculators and risk factors for Scleroderma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Given the difficulty in treating scleroderma, treatments with a smaller evidence base are often tried to control the disease. These include antithymocyte globulin and mycophenolate mofetil; some reports have reported improvements in the skin symptoms as well as delaying the progress of systemic disease, but neither of them have been subjected to large clinical trials.[1]
While still experimental (given its high rate of complications), hematopoietic stem cell transplantation is being studied in patients with severe systemic sclerosis; improvement in life expectancy and severity of skin changes has been noted.[2]
References
- ↑ Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y (2005). "New therapeutic strategies for systemic sclerosis--a critical analysis of the literature". Clin. Dev. Immunol. 12 (3): 165–73. PMID 16295521. PMC 2275417
- ↑ Nash RA, McSweeney PA, Crofford LJ; et al. (2007). "High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the U.S. multicenter pilot study". Blood. 110 (4): 1388–96. doi:10.1182/blood-2007-02-072389. PMID 17452515.